WallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Stock

Overview
ForecastEarningsDividendOwnership
$57.13+0.30 (+0.53%)
Updated Dec 7, 2021
BMY Price
$57.13
Fair Value Price
N/A
Market Cap
$129.27B
52 Week Low
$53.22
52 Week High
$69.75
P/E
-24.11x
P/B
3.47x
P/S
2.89x
PEG
N/A
Dividend Yield
3.43%
Revenue
$45.47B
Earnings
-$5.41B
Gross Margin
76.9%
Operating Margin
-9.31%
Profit Margin
-11.9%
Debt to Equity
1.98
Operating Cash Flow
$16B
Beta
0.65
Next Earnings
Feb 4, 2022
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

Expand Score
High
Medium
Low
27
Industry average

Reasons for this score

BMY is good value based on its book value relative to its share price (3.47x), compared to the US Drug Manufacturers - General industry average (4.91x)
Valuation
BMY's Earnings (EBIT) of -$4.23B are insufficient to safely cover interest payments on company debt ($44.74B)
Financials
BMY's profit margin has decreased (-11.8%) in the last year from (-0.1%) to (-11.9%)
Financials

1 of 9

BMY News

Valuation

BMY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-24.11x
Industry
24.87x
Market
37.78x

BMY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.47x
Industry
4.91x
BMY is good value based on its book value relative to its share price (3.47x), compared to the US Drug Manufacturers - General industry average (4.91x)
Valuation

BMY's financial health

Profit margin

Revenue
$11.6B
Net Income
$1.5B
Profit Margin
13.3%
BMY's Earnings (EBIT) of -$4.23B are insufficient to safely cover interest payments on company debt ($44.74B)
Financials
BMY's profit margin has decreased (-11.8%) in the last year from (-0.1%) to (-11.9%)
Financials

Assets to liabilities

Assets
$110.9B
Liabilities
$73.6B
Debt to equity
1.2
BMY's short-term assets ($31.44B) exceed its short-term liabilities ($21.46B)
Financials
BMY's long-term liabilities ($52.15B) exceed its short-term assets ($31.44B)
Financials
BMY's debt has increased relative to shareholder equity (1.98), over the past 5 years ago (1.15)
Financials
BMY's debt to equity ratio (1.98) is considered high
Financials

Cash flow

Operating
$5.3B
Investing
-$976.0M
Financing
-$1.8B
BMY's operating cash flow ($15.82B) is sufficient to service the company's debt ($44.74B)
Financials

Bristol Myers Squibb Stock FAQ

What is Bristol Myers Squibb's quote symbol?

(NYSE: BMY) Bristol Myers Squibb trades on the NYSE under the ticker symbol BMY. Bristol Myers Squibb stock quotes can also be displayed as NYSE: BMY.

What is the 52 week high and low for Bristol Myers Squibb (NYSE: BMY)?

(NYSE: BMY) Bristol Myers Squibb's 52-week high was $69.75, and its 52-week low was $53.22. It is currently -18.09% from its 52-week high and 7.35% from its 52-week low.

How much is Bristol Myers Squibb stock worth today?

(NYSE: BMY) Bristol Myers Squibb currently has 2,219,644,935 outstanding shares. With Bristol Myers Squibb stock trading at $57.13 per share, the total value of Bristol Myers Squibb stock (market capitalization) is $129.27B.

Bristol Myers Squibb stock was originally listed at a price of $47.32 in Dec 31, 1997. If you had invested in Bristol Myers Squibb stock at $47.32, your return over the last 23 years would have been 20.74%, for an annualized return of 0.82% (not including any dividends or dividend reinvestments).

How much is Bristol Myers Squibb's stock price per share?

(NYSE: BMY) Bristol Myers Squibb stock price per share is $57.13 today (as of Dec 7, 2021).

What is Bristol Myers Squibb's Market Cap?

(NYSE: BMY) Bristol Myers Squibb's market cap is $129.27B, as of Dec 8, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bristol Myers Squibb's market cap is calculated by multiplying BMY's current stock price of $57.13 by BMY's total outstanding shares of 2,219,644,935.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.